Tagged oncology
Powerhouses QCCA and NCCA Merge to Create a Transformative New Entity in Independent Practice Oncology and Cancer Care: ONCare Alliance, LLC
After years of successful collaboration, the esteemed organizations National Cancer Care Alliance (NCCA) and Quality Cancer Care Alliance (QCCA) have merged, culminating in the birth of a transformative new entity, ONCare Alliance, LLC.
Read More
Comprehensive Hematology Oncology, LLC Becomes the 20th Practice to Join QCCA’s National CIN of Independent Cancer Care Practices
Quality Cancer Care Alliance’s Nationwide Network of Independent Community Oncology Practices Welcomes Comprehensive Hematology Oncology, LLC, With Eight Locations Serving St. Petersburg-Tampa Bay Communities
Read More
A New Publication Highlights the Use of cResponse in the Assessment of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer
A recent publication in "Cancer Discovery" reviewed Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) spectrum of responses to platinum and PARPi therapy, exploring the genomic and clinical features that may lead to different responses, and investigates the mechanisms of resistance.
Read More
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
Read More
BioNTech Establishes Asia-Pacific Clinical Scale mRNA Manufacturing & Regional Research Centre
German-based biotechnology company BioNTech will establish a clinical scale research mRNA manufacturing facility in Australia, following an in-principle letter of intent signed with the Victorian Government.
Read More
CytoImmune Therapeutics Announces Publication Demonstrating Platelet-Derived Growth Factor D Signaling Activates Natural Killer (NK) Cells and Enhances NK Cell Survival
A PNAS study demonstrates platelet-derived growth factor D (PDGF-D) binding to PDGF receptor-beta (PDGFRβ) activates NK cells to enhance interleukin (IL)-15-mediated NK cell survival.
City of Hope research suggests that the selective introduction of PDGF signaling in NK cells by IL-15 should benefit NK cell expansion and persistence and/or enhance effector function in NK cell-based immunotherapies.
